Bromelain

2 studies · 1 supporting · 1 against

Proposed proteolytic and anti-inflammatory action reducing bradykinin and inflammatory mediator activity at the joint.

Dose: 500–800 mg

Tested as: oral bromelain (stem-derived enzyme concentrate), 500-800 mg/day — knee osteoarthritis

1 study · 1 supporting · 0 against

Proposed proteolytic action that may reduce circulating pro-inflammatory cytokines and acute-phase proteins such as CRP.

Dose: 200–1050 mg

Tested as: oral bromelain alone, 200-1050 mg/day for 1-16 weeks — effect on blood inflammatory markers (CRP, IL-6, TNF-alpha etc.), not a specific inflammatory disease

1 study · 0 supporting · 1 against

How it was tested: Bromelain (300 mg t.i.d.) and ibuprofen (400 mg t.i.d.) both had no effect on elbow-flexor pain, range-of-motion loss, or peak torque loss versus placebo/control after eccentric exercise.

Proposed proteolytic/anti-inflammatory action that in theory could reduce inflammatory mediators generated by exercise-induced muscle micro-damage.

Dose: 900 mg

Tested as: oral bromelain, 300 mg three times daily (900 mg/day) — delayed-onset muscle soreness (DOMS) after eccentric exercise